Roche's Actemra falls short in Italian study in early-stage COVID-19 pneumonia How Regeneron’s COVID-19 antibody cocktail cuts the risk of resistance Providers to Congress: Patients will lose access to care without permanent expansion of telehealth How to launch a drug in a pandemic? Here's how 4 drugmakers are using digital tools and fast footwork to do just that FDA joins new, public-private COVID-19 diagnostic research accelerator effort Mostashari: The survival of primary care is critical to fight COVID-19 Biopharma roundup: E.U. members line up for J&J vaccine; Actemra stumbles in COVID-19 pneumonia trial Healthcare roundup: Blue Cross NC keeping expanded telehealth policies through 2020 Kaiser Permanente, Cambia CEOs: How payer execs adapted their leadership styles under COVID-19 Featured Story | Thursday, June 18, 2020 In another challenge to the theory that IL-6 inhibitors can treat coronavirus patients, and Italian study found Roche’s anti-inflammatory drug Actemra didn’t help patients with early-stage COVID-19 pneumonia. But Roche is pressing ahead with its own tests in more severe patients—and ramping up manufacturing, too. read more |
| |
|---|
|
Top Stories Thursday, June 18, 2020 Regeneron launched human trials of its anti-COVID cocktail REGN-COV2 last week, and now its scientists are explaining how they chose the two antibodies that comprise the treatment. The key was to thwart the ability of the virus to mutate by selecting antibodies that bind differently to their target, they explained in a new study. read more Thursday, June 18, 2020 Patients will lose access to care if Congress doesn't take immediate steps to expand telehealth permanently, health executives told lawmakers Wednesday. read more Thursday, June 18, 2020 Launching a new drug is an arduous task even in the best of times, with months of effort and huge sums of money on the line. Add a global pandemic to that, and companies are faced with one of two options: Adapt or fail. read more Thursday, June 18, 2020 The FDA has joined a public-private diagnostic research project with the goal of bringing more real-world data to bear against the novel coronavirus, and gauging the accuracy of different kinds of tests. read more Thursday, June 18, 2020 The federal government has done "nothing special" to help primary care practices, according to Farzad Mostashari, M.D. Find out why Mostashari says primary care practices will the lifeblood of communities in the ongoing pandemic and in the "new normal." read more Thursday, June 18, 2020 As European nations look to score advanced purchase deals for COVID-19 vaccines, some experts worry that low-income countries won't receive the treatments they need. Emergent invested $75 million to upgrade its gene therapy business, and Regeneron touted the strength of its antibody cocktail. Plus, Actemra sputtered in an early-stage COVID-19 pneumonia trial. read more Thursday, June 18, 2020 Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more Thursday, June 18, 2020 The coronavirus pandemic forced the CEOs of some of the country’s biggest payers to rethink their approaches to leadership. read more |
